Cutting Copays Act

Bill: 119-hr-4139
Sponsor: full_name: Rep. McGarvey, Morgan [D-KY-3]
Introduced: 2025-06-25
Policy area: Health
Latest action: action_date: 2025-06-25
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summaries:
action_date: 2025-06-25
action_desc: Introduced in House
text: <p><strong>Cutting Copays Act</strong></p><p>This bill eliminates cost-sharing for generic drugs for those with the lowest-income under the Medicare prescription drug benefit's Low-Income Subsidy Program beginning in 2026.</p>

tv_txt: I 119th CONGRESS 1st Session H. R. 4139 IN THE HOUSE OF REPRESENTATIVES June 25, 2025 Mr. McGarvey (for himself and Mr. Bilirakis ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to provide for adjustments to the Medicare part D cost-sharing reductions for low-income individuals.

1. Short title This Act may be cited as the Cutting Copays Act . 2. Adjustments to Medicare part D cost-sharing reductions for low-income individuals Section 1860D–14(a) of the Social Security Act ( 42 U.S.C. 1395w–114(a) ) is amended in paragraph (1)(D)(ii)— (1) by striking that does not exceed $1 for and all that follows through the period at the end and inserting that does not exceed— (I) for plan years before plan year 2026— (aa) for a generic drug or a preferred drug that is a multiple source drug (as defined in section 1927(k)(7)(A)(i)), $1 or, if less, the copayment amount applicable to an individual under clause (iii); and (bb) for any other drug, $3 or, if less, the copayment amount applicable to an individual under clause (iii); and ; and (2) by adding at the end the following new subclauses: (II) for plan year 2026— (aa) for a generic drug, $0; and (bb) for any other drug, the dollar amount applied under this clause (after application of paragraph (4)(A)) for plan year 2023 for a drug described in subclause (I)(bb); and (III) for a subsequent year, the dollar amount applied under this clause for the previous year for the drug, increased by the annual percentage increase in the consumer price index (all items; U.S. city average) as of September of such previous year. .